

Evaluating the Potential Role
of **NEXT-GENERATION
SELECTIVE ESTROGEN
RECEPTOR DEGRADERS**
in the ER+/HER2- Breast Cancer
Treatment Paradigm

SATURDAY, JUNE 4, 2022

7:00 PM - 9:00 PM CDT

PROGRAM CHAIR

Aditya Bardia, MD, MPH

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer® the ASCO Foundation.

For more information, visit us at...

gotoper.com



STAY CONNECTED! Follow us @GoToPER and share your thoughts by using #gotoper.

Dear Colleague,

On behalf of Physicians' Education Resource®, LLC (PER®), we would like to welcome you and thank you for choosing to attend **Medical Crossfire®: Evaluating the Potential Role of Next-Generation Selective Estrogen Receptor Degraders in the ER+/HER2- Breast Cancer Treatment Paradigm.**

This CME-certified satellite will deliver you differing and provocative opinions on treatment approaches from a panel of experts in the management of breast cancer. The program includes didactic lectures that will provide you with the most current knowledge of the underlying biology of HR+ breast cancer and rationale for new drug targets, up-to-date information regarding the efficacy and safety of emerging oral SERDs, and an understanding of how these investigational drugs may fit in with existing treatments for ER+ breast cancer. In the "Medical Crossfire" portion of the program, detailed case presentations and panel discussions on controversial issues will offer you an intimate look into how experts approach the individualized management of patients with ER+/HER2- breast cancer.

In working together with PER®, we strive to make this activity, along with all PER® accredited continuing education (CE) activities, both useful and impactful for health care professionals like you who are involved with the care of patients with breast cancer.

If there is anything additional that you need, if you experience an issue, or if you have an idea for a future activity that would help you in the care of your patients, please let us know.

We could not have our accredited CE activities without you, and we appreciate your commitment to learning about the latest advancements in the treatment of cancer. Let's work together to make this an educational experience that will make a positive difference for our patients!

We hope you enjoy your experience at this first-class PER® symposium and that you can attend another PER® accredited CE activity soon.

Regards,

Aditya Bardia, MD, MPH

Director, Breast Cancer Research Program
Associate Professor, Harvard Medical School
Attending Physician, Medical Oncology
Massachusetts General Hospital
Boston, MA

Phil Talamo, CHCP

President
Physicians' Education Resource®, LLC
Cranbury, NJ
ptalamo@gotoper.com

AGENDA

7:00 PM	Welcome and Introductions	Aditya Bardia, MD, MPH
7:10 PM	ER+ /HER2- Metastatic Breast Cancer: Background Information	Nicholas Turner, MD, PhD
7:20 PM	Current Management Considerations for ER+ /HER2- Metastatic Breast Cancer	Erika P. Hamilton, MD
8:00 PM	Novel Advances in ER+ Breast Cancer: Next-Generation SERDs	Komal Jhaveri, MD, FACP
8:40 PM	Audience Q&A Session	Moderator: Aditya Bardia, MD, MPH
8:45 PM	What's on Your Radar for the Annual Clinical Oncology Conference? Panel Discussion	Moderator: Aditya Bardia, MD, MPH
8:50 PM	Summary and Conclusions	Aditya Bardia, MD, MPH
9:00 PM	Adjourn	

Upcoming PER® Conferences			2022
	6th Annual International Congress on Oncology & Pathology™: Towards Harmonization of Pathology and Oncology Standards		June 25
	21st Annual International Congress on the Future of Breast Cancer® East	New York City, NY	July 15-16
	6th Annual Live Medical Crossfire®: Hematologic Malignancies	New York City, NY	July 16
	23rd Annual International Lung Cancer Congress®	Huntington Beach, CA	July 28-30
	21st Annual International Congress on the Future of Breast Cancer® West	San Diego, CA	July 29-30
	6th Annual School of Nursing Oncology	San Diego, CA	July 29-30
	20th Annual School of Breast Oncology®	Atlanta, GA	November 3-5
	40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®	New York City, NY	November 9-11
	17th Annual New York Lung Cancers Symposium	New York City, NY	November 12
	7th Annual International Congress on Immunotherapies in Cancer™	New York City, NY	December 10



Virtual Conference



In-Person + Virtual Conference

Target Audience

This educational activity is directed toward medical oncologists, surgical oncologists, and other HCPs involved in the treatment of breast cancer.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

- Describe efficacy and safety data of next-generation SERD agents for the management of HR+/HER2- breast cancer
- Explain how patient and tumoral characteristics can be aligned with clinical trial evidence to inform decision-making in the management of HR+/HER2- breast cancer
- Apply recent trial evidence to manage case scenarios typically encountered in HR+/HER2- breast cancer care and in consideration of evolving treatment paradigms in the field
- Determine ongoing trials concerning SERDs that are intended to address clinical gaps in the field of HR+/HER2- breast cancer management

Slides/e-Syllabus

Final slides will be uploaded to the e-syllabus on the PER[®] website by 12:00 PM EDT on Monday, June 6. To access these materials, please visit <http://www.gotoper.com/serds0622iss-esyll>

How to Request Credit

To complete the online evaluation and receive a certificate of credit or participation, please visit

<http://www.gotoper.com/serds0622iss-eval>

The online evaluation and request for credit will be available immediately following the program and will remain available until September 4, 2022.

Accreditation/Designation of Credit

Physicians' Education Resource[®], LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource[®], LLC designates this live activity for a maximum of 2.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Menarini-Stemline.

Thank you for attending **Medical Crossfire[®]: Evaluating the Potential Role of Next-Generation Selective Estrogen Receptor Degraders in the ER+/HER2- Breast Cancer Treatment Paradigm**

To register for upcoming accredited CE live activities or to view our online accredited CE activities, please visit www.gotoper.com.

We appreciate your attendance and look forward to seeing you at future PER[®] accredited CE activities.

Faculty, Staff, and Planners' Disclosures

The following individuals have no relevant financial relationships with ineligible companies to disclose: the staff of Physicians' Education Resource®, LLC.

The following individuals have relevant financial relationships with ineligible companies to disclose*:

Faculty	Grant/Research Support	Consultant	Speakers' Bureau	Other
Aditya Bardia, MD, MPH	Daiichi Pharma/Astra Zeneca, Eli Lilly, Genentech, Immunomedics/Gilead, Merck, Novartis, Pfizer, Radius Health, Sanofi	Daiichi Pharma/Astra Zeneca, Eli Lilly, Foundation Medicine, Genentech, Immunomedics/Gilead, Merck, Novartis, Pfizer, Philips, Radius Health, Sanofi		
Erika P. Hamilton, MD	RESEARCH FUNDING-ALL PAYMENTS TO INSTITUTION AbbVie, Acerta Pharma, ADC Therapeutics, Akesobio, Amgen, Aravive, ArQule Arvinas, AstraZeneca, Atlas Medx, Black Diamond Therapeutics, Boehringer Ingelheim, Clovis Oncology, Compugen, Curis, CytomX, Daiichi Sankyo, Dana-Farber Cancer Institute, Deciphera, eFFECTOR Therapeutics, Ellipses Pharma, EMD Serono, Fochon, Fujifilm, G1 Therapeutics, H3 Biomedicine, Hutchison MediPharma, Immunogen, Immunomedics, Incyte, InvestisBio, Jacobio, Karyopharm, Leap Therapeutics, Lilly, Lycera, MabSpace Biosciences, MacroGenics, MedImmune, Merck, Mersana, Merus, Millennium Pharmaceuticals, Molecular Templates, Myriad Genetic Laboratories, Novartis, Nucana, Olema Pharmaceuticals, OncoMed, Onconova Therapeutics, Ori Biotech, Orinove, Pfizer, PharmaMar, Pieris Pharmaceuticals, Pionyr Immunotherapeutics, Plexxikon, Radius Health, Regeneron, Repertoire Immune Medicines, Rgenix, Roche/Genentech, Seagen, Sermonix Pharmaceuticals, Shattuck Labs, Silverback, Stemcentrx, Sutro Biopharma, Syndax, Syros, Taiho Oncology, Tapimmune, Tesaro, Treadwell Therapeutics, Verastem, Vincerox Pharma, Zenith Epigenetics, Zymeworks	Arcus, Arvinas AstraZeneca, Black Diamond Therapeutics, Boehringer Ingelheim, CytomX, Daiichi Sankyo, Dantari, Deciphera, Eisai, H3 Biomedicine, iTeos, Janssen, Lilly, Loxo Oncology, Merck, Mersana, Novartis, Pfizer, Puma Biotechnology, Relay Therapeutics, Roche/Genentech, Seagen, Silverback Therapeutics		
Komal Jhaveri, MD, FACP	AstraZeneca, Genentech, Immunomedics/Gilead, Novartis, Lilly Pharmaceuticals/ Loxo Oncology, Merck/ VelosBio, Novartis, Pfizer, Puma Biotechnology, Zymeworks	AbbVie, AstraZeneca, Blueprint Medicines, Biotheranostics, Genentech, Lilly Pharmaceuticals/Loxo Oncology, Novartis, Pfizer, Seagen, Sun Pharma Pvt Ltd, Taiho Oncology		

**Nicholas Turner, MD, PhD

**Information accurate at time of posting*

***Disclosure not received at the time of printing this workbook. Dr. Turner will disclose relationships with ineligible companies as part of his presentation.*

PER[®] has identified and mitigated all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer


This accredited CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing medical and/or nursing education purposes only and is not meant to substitute for the independent clinical judgment of a physician or nurse relative to the diagnostic, treatment, and management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER[®] or any of the companies that provided commercial support for this activity.

Physician Payments Sunshine Act

PER[®] complies with the Physician Payments Sunshine Act as a part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfers of value provided to any covered recipient under the ACA.

Experience
the new
gotoper.com



Streamlining
education
for the busy
clinician



Program Chair



Aditya Bardia, MD, MPH

Associate Professor
Harvard Medical School
Attending Physician, Medical Oncology
Massachusetts General Hospital
Boston, MA

Aditya Bardia, MD, MPH, a board-certified medical oncologist, is an attending physician at Massachusetts General Hospital (MGH) Cancer Center (Mass General Cancer Center), Harvard Medical School, in Boston, Massachusetts. As the director of the breast cancer research program at its Center for Breast Cancer, Dr. Bardia is interested in advancing research to improve the outcomes with breast cancer. Dr. Bardia has led the clinical development of the antibody drug conjugate (ADC), sacituzumab govitecan, the first ADC approved for patients with metastatic triple negative breast cancer.

Dr. Bardia has received several research awards, including outstanding award for research excellence at the Mayo Clinic in Rochester, Minnesota; Young Investigator Award from the American Society of Clinical Oncology (ASCO), and the Douglass Family Foundation prize for excellence in oncology research at MGH. Bardia is the editor of the precision medicine clinic section of *The Oncologist*; coleader of the Molecular and Precision (MAP) tumor board at MGH; and editorial board member of ASCO molecular oncology tumor board.

Faculty



Erika P. Hamilton, MD

Director
Breast and Gynecologic Cancer Research Program
Sarah Cannon Research Institute
Nashville, TN

Erika P. Hamilton, MD, joined the Sarah Cannon Research Institute in 2013 and was promoted to director of its breast and gynecologic research program in 2016. Dr. Hamilton cares for patients with breast and gynecologic cancer. As the director, she oversees the program and the clinical trial menu for these cancers across the Sarah Cannon network. Additionally, she is a partner with Tennessee Oncology, PLLC.

After receiving an undergraduate degree from Washington and Lee University in Lexington, Virginia, Dr. Hamilton completed her medical degree and residency at the University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University in Durham, North Carolina, where she was recognized as a Top 5 Finalist for Duke's annual house staff fellow teaching award. She is board certified in internal medicine and oncology.

**Komal Jhaveri, MD, FACP**

Medical Oncologist

Memorial Sloan Kettering Cancer Center

New York, NY

Komal Jhaveri, MD, FACP graduated from the University of Mumbai, completed her training in internal medicine at St Luke's Roosevelt Hospital in New York. She then went on to complete her Medical Oncology and Hematology training at MSKCC. From July 2012-May 2015, she served as an Assistant Professor in the Division of Hematology/Medical Oncology, in the Department of Medicine at NYU and as an Attending Physician at the Langone Medical Center and at Bellevue Hospital.

She is currently an Assistant Attending Physician and has dual appointment within the Breast Medicine and Early Drug Development Service at MSKCC. She is also an Assistant Professor in the Department of Medicine at Weill Cornell Medicine in New York City. Within the Breast medicine Service, she serves as the Section Head for the Endocrine Therapy Research Program and manages the entire clinical trial portfolio for this subtype of breast cancer.

Her career goal is focused on clinical and translational research by accelerating rational therapeutic options for patients with metastatic disease and improving their outcomes. Specifically, she conducts novel clinical trials through translational biomarker work. She conducts companion translational research in collaboration with her laboratory and imaging colleagues and is focused on identifying and understanding the biomarkers of response or resistance to novel therapies through acquired biospecimen (cfDNA and tumor) or imaging analyses. She has led the development of many targeted therapies including and not limited to PI3K inhibitors, oral SERD's, Antibody-drug conjugates, amongst others.

Dr. Jhaveri has served on the ASCO Cancer Research Committee and currently serves as a member of the ASCO/TAPUR Molecular Tumor Board. She is also a member of the Endocrine Resistance working group within the Translational Breast Cancer Research Consortium. Her work has been presented at annual scientific meetings of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR) and the San Antonio Breast Cancer Symposium (SABCS) and has been published widely in many reputable journals.

**Nicholas Turner, MD, PhD**

Academic Consultant
Medical Oncologist
Biomedical Research Centre
The Royal Marsden NHS Foundation Trust
The Institute of Cancer Research
London, England, UK

Nicholas Turner, MD, PhD, is a consultant medical oncologist who specializes in the treatment of breast cancer. He attended the Dr Turner read Natural Sciences at Cambridge University before qualifying in 1997 from the University of Oxford Medical School.

After completing general medical training in London, he trained in medical oncology at Royal Free and University College Hospitals and completed a PhD at The Institute of Cancer Research in 2006. He joined the breast unit of The Royal Marsden as a consultant in medical oncology in 2008.

Dr. Turner is a team leader in molecular oncology at the Breast Cancer Now Research Centre at the ICR. He is breast theme lead for The Royal Marsden National Institute for Health and Care Research Biomedical Research Centre, and a member of the National Cancer Research Institute breast cancer clinical studies group.

He is the breast domain lead of the Genomics England Clinical Interpretation Partnership. He serves on the organizing committees of many international conferences on breast cancer and was the executive chair of the IMPAKT 2015 breast cancer conference. He also is a scientific editor of the journal *Cancer Discovery*.

Professor Turner is chief investigator of several national and international trials of precision therapy in breast cancer. His research interests include the development of new therapies for breast cancer and using liquid biopsies to deliver more precise treatment.

ASCO Direct™

HIGHLIGHTS

2022 Official Annual Meeting Review

Learn from leading experts about important, potentially practice-changing data in oncology and hematology.

Dallas, TX
June 18

Charlotte, NC
July 9

Nashville, TN
July 9

New York, NY
July 23

VIRTUAL
OPTIONS
AVAILABLE

40% off registration! Use code **ADH22**



Scan with smartphone
to explore the series

PER®
Physicians'
Education
Resource, LLC
gotoper.com

**CELEBRATE THE 40TH ANNIVERSARY
OF CFS® LIVE IN NYC**

40th Annual
CFS®

Chemotherapy Foundation
SYMPOSIUM

Innovative Cancer Therapy for Tomorrow®

SAVE
THE
DATE!

NOVEMBER 9 – 11, 2022

New York Marriott Marquis • New York, NY

In-person + Virtual Conference

This activity
is approved
for AMA PRA
Category 1
Credit™.



100 EXPERT
FACULTY
MEMBERS



25 TUMOR
TYPES



3 DAYS



1 MEETING

35% off registration! Use code **CFS22BF**



Scan with smartphone or visit the link below
gotoper.com/cfs22

PER®
Physicians'
Education
Resource, LLC
gotoper.com